Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Diabetes Mellitus Type 2
Clinical trial register · United States · industry-sponsored

Diabetes Mellitus Type 2 Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
Florida 17 California 17 Georgia 9 Arizona 8 Illinois 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Diabetes Mellitus Type 2 trials in the USA

25 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Novo Nordisk A/S
Phase 3
210
Arizona, California, Connecticut, Florida, Hawaii, Illinois, Iowa, Kansas
2026-09-16
Not yet open
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
By invitation
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
NCT07197788Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Not applicable
50
Florida, Massachusetts, New Jersey, North Carolina, Texas
2026-09
Recruiting
AstraZeneca
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2026-08-20
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
Novo Nordisk A/S
Phase 2
300
Alabama, California, Florida, Indiana, Kansas, Maryland, North Carolina, North Dakota
2026-06-22
Recruiting
Amgen
Phase 1
162
California, Florida
2026-06-11
Not yet open
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Not yet open
Argus 2.0 Adoption Study
NCT07425236Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
KOS Inc.
Not applicable
100
California
2026-04-19
Recruiting
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
By invitation
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
NCT07197775Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes
Endogenex, Inc.
Observational
500
Massachusetts, North Carolina, Texas
2026-03-11
Recruiting
ROME GS System Study
NCT07518004Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2
Senseonics, Inc.
Not applicable
60
California, Texas, Washington
2026-02-12
Recruiting
Senseonics, Inc.
Not applicable
80
California
2025-12-29
Active, closed
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Active, closed
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-07-22
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
Recruiting
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
NCT06567795Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease
Aventusoft, LLC.
Observational
189
Florida
2024-03-14
Recruiting
Cleerly, Inc.
Not applicable
7,500
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-03-06
Active, closed
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Active, closed
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
NCT05874635Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
Signos Inc
Not applicable
20,000
California
2023-05-11
Active, closed
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
NCT05464784Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
MediciNova
Phase 2
40
Nevada, Texas
2022-08-22
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2019-05-08
By invitation
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
NCT01511393Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
Novo Nordisk A/S
Observational
6,750
West Virginia
2012-01
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/diabetes-mellitus-type-2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 19 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies listing the condition Diabetes Mellitus Type 2.

How many Diabetes Mellitus Type 2 trials are recruiting in the US?

12 of the 25 studies on this page are recruiting new participants as of the 19 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 7 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diabetes Mellitus Type 2), 25 studies
PhaseStudiesRecruitingShare
Phase 39536%
Not applicable7328%
Phase 25220%
Observational3112%
Phase 1114%

Most active sponsors

Lead sponsors with the most studies (Diabetes Mellitus Type 2)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S74
Eli Lilly and Company40
Endogenex, Inc.30
Amgen22
Senseonics, Inc.22
AstraZeneca11
Aventusoft, LLC.11
Boehringer Ingelheim11
Cleerly, Inc.11
KOS Inc.10

Top states

Top states (Diabetes Mellitus Type 2), by number of studies with a site there
StateStudies
California17
Florida17
Georgia9
Arizona8
Illinois8
Texas6
Alabama5
Connecticut5
Idaho5
Indiana5
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.